Legal Representation
Attorney
Brian R. Coleman
USPTO Deadlines
Application History
23 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 24, 2006 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Oct 24, 2006 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Jan 23, 2006 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jan 23, 2006 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Jan 23, 2006 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Nov 4, 2005 | PROA | I | TEAS PETITION TO REVIVE RECEIVED | Loading... |
| Nov 4, 2005 | PETG | O | PETITION TO REVIVE-GRANTED | Loading... |
| Nov 4, 2005 | TPEX | I | SOU EXTENSION RECEIVED WITH TEAS PETITION | Loading... |
| Oct 25, 2005 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Oct 24, 2005 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Oct 24, 2005 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Aug 24, 2005 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Jan 24, 2005 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Jan 3, 2005 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jan 3, 2005 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Mar 31, 2004 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 31, 2004 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Mar 31, 2004 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Feb 24, 2004 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Dec 2, 2003 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Nov 12, 2003 | NPUB | O | NOTICE OF PUBLICATION | Loading... |
| Sep 21, 2003 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Sep 21, 2003 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Detailed Classifications
Class 005
Biopharmaceuticals for use in the diagnosis, prevention, and treatment of human and animal diseases, namely cancer, viral infections, microbial infections, autoimmune diseases, allergies, immunological dysfunctions, neurological disorders, blood disorders, and inflammatory diseases
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005